-
Anthem Biosciences Analyst Review 2027: Q2 Profit Beat Keeps Brokers at ₹1,000 to ₹1,050
- November 19, 2026
- Posted by: Chaitanya Auti
- Category: Market
No Comments
Anthem Biosciences grew Q2 FY27 profit about 22% to ₹211 crore on an EBITDA margin above 50%, beating PL Capital’s estimate. PL Capital holds a ₹1,050 target and JPMorgan ₹1,000. We review brokerage views, results, the CRDMO model, valuation and risks.